Veliparib hydrochloride: Poly(ADP-ribose)polymerase inhibitor oncolytic

Drugs of the Future

Volumn 35, Issue 10, 2010, Pages 815-822

  Lepeak, L M ^a   Leal, T ^a   Robins, H I ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 861695; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NSC 737664; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB;

ACUTE LEUKEMIA; ADD ON THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BRAIN RADIATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DNA DAMAGE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLASMA CONCENTRATION-TIME CURVE; PROSTATE CANCER; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

EID: 79956199846     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.010.1526315     Document Type: Review

References (40)

1. Zhu, G.-D., Gong, J., Gandhi, V.B., Penning, T.D., Giranda, V.L. (Abbott Laboratories, Inc.). 1H-Benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors. EP 1869011, JP 2008535926, US 2006229289, WO 2006110816.
2. Penning, T.D., Zhu, G.D., Gandhi, V.B. et al. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H- benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 2009, 52(2): 514-23.
3. Shall, S., de Murcia, G. Poly(ADP-ribose) polymerase-1: What have we learned from the deficient mouse model? Mutat Res 2000, 460(1): 1-15.
4. Masutani, M., Nozaki, T., Nakamoto, K. et al. The response of PARP knockout mice against DNA damaging agents. Mutat Res 2000, 462(2-3): 159-66. (Pubitemid 30190223)
5. Ame, J.C., Rolli, V., Schreiber, V. et al. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999, 274(25): 17860-8.
6. Menissier de Murcia, J., Ricoul, M., Tartier, L. et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003, 22(9): 2255-63. (Pubitemid 36565548)
7. Virag, L., Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54(3): 375-429.
8. Hayaishi, O., Ueda, K. Poly(ADP-ribose) and ADP-ribosylation of proteins. Annu Rev Biochem 1977, 46: 95-116.
9. Tomoda, T., Kurashige, T., Moriki, T., Yamamoto, H., Fujimoto, S., Taniguchi, T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991, 37(4): 223-7.
10. Shiobara, M., Miyazaki, M., Ito, H. et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001, 16(3): 338-44. (Pubitemid 32374852)
11. Fukushima, M., Kuzuya, K., Ota, K., Ikai, K. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett 1981, 14(3): 227-36. (Pubitemid 12223479)
12. O'Shaughnessy, J., Osborne, C., Pippen, J. et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 3.
13. Farmer, H., McCabe, N., Lord, C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035): 917-21. (Pubitemid 40559006)
14. Bryant, H.E., Schultz, N., Thomas, H.D. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035): 913-7. (Pubitemid 40559005)
15. Iglehart, J.D., Silver, D.P. Synthetic lethality - A new direction in cancerdrug development. N Engl J Med 2009, 361(2): 189-91.
16. Fong, P.C., Boss, D.S., Yap, T.A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2): 123-34.
17. Tutt, A., Robson, M., Garber, J.E. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010, 376(9737): 235-44.
18. Audeh, M.W., Carmichael, J., Penson, R.T. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010, 376(9737): 245-51.
19. Donawho, C.K., Luo, Y., Penning, T.D. et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007, 13(9): 2728-37. (Pubitemid 46795129)
20. Albert, J.M., Cao, C., Kim, K.W. et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13(10): 3033-42. (Pubitemid 46849580)
21. Palma, J.P., Wang, Y.C., Rodriguez, L.E. et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009, 15(23): 7277-90.
22. Hegi, M.E,. Diserens, A.C., Gorlia, T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10): 997-1003. (Pubitemid 40349502)
23. Denny, B.J., Wheelhouse, R.T., Stevens, M.F., Tsang, L.L., Slack, J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994, 33(31): 9045-51. (Pubitemid 24272851)
24. Tentori, L., Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005, 52(1): 25-33. (Pubitemid 40725597)
25. Tentori, L., Orlando, L., Lacal, P.M. et al. Inhibition of O6-alkylguanine DNA-alkyl transferase or poly (ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 1997, 52(2): 249-58. (Pubitemid 27349616)
26. Wedge, S.R., Porteous, J.K., Newlands, E.S. 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996, 74(7): 1030-6. (Pubitemid 26333902)
27. Horton, T.M., Jenkins, G., Pati, D. et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009, 8(8): 2232-42.
28. Muscal, J.A., Thompson, P.A., Giranda, V.L. et al. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol 2010, 65(3): 419-25.
29. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 1019.
30. Molina, J., Northfeld, D., Erlichman, C., Lensing, J., Luo, Y., Giranda, V. Ongoing phase 1 studies of a novel PARP inhibitor, ABT-888: Pharmacokinetics, safety and anti-tumor activity. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 3602.
31. Kummar, S., Ji, J., Zhang, Y. et al. A phase I combination study of ABT-888 and topotecan hydrochloride in adults with refractory solid tumors and lymphomas. Ann Oncol 2009, 20(Suppl. 3): G03.
32. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 3580.
33. Kummar, S., Kinders, R., Gutierrez, M.E. et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009, 27(16): 2705-11.
34. Jaxel, C., Kohn, K., Wani, M., Wall, M., Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989, 49(6): 1465-9. (Pubitemid 19088683)
35. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2514.
36. th Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 17-20, Atlanta) 2010] 2010, 87(Suppl. 1): Abst PIII-30.
37. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3000.
38. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2605.
39. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst TPS168.
40. Stupp, R., Mason, W.P., van den Bent, M.J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10): 987-96. (Pubitemid 40349501)